SMSbiotech has a Phase 1 clinical trial underway in Australia for its COPD program with an FDA-granted IND.

SMSbiotech is a San Diego based biotech company utilizing a novel human stem cell to advance the field of regenerative medicine. Currently, many conventional drugs and treatments address patients’ symptoms instead of the root causes of the disease. This approach can result in ongoing health issues like non-healing wounds or diseases we merely live with like COPD. SMSbiotech’s patented regenerative technology intends to change this status quo. Its approach addresses the lack of ability of many patients to restore cells and tissues that have been damaged by disease or trauma. The healthy human body has an innate ability to heal and the drive to protect itself. When the mechanisms that signal this response are impaired, the body needs assistance to restore that ability. SMSbiotech has established a newly discovered technology that is largely donor independent and ethically sourced from living, human adults. By using the right source and tapping scientifically into that inherent mechanism for regeneration, therapies and treatments can be developed to assist the human body in healing. SMSbiotech technology will lead to the development of more efficient and relevant medicines that will serve a broad spectrum of patients and reduce the overall costs of healthcare.